15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Silence Therapeutics PLC, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $32.00 to $75.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $53.50 sits 291% above the current $13.69. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Silence Therapeutics PLC.
As of Sep, 3 of 3 firms rate SLN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SLN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.24 – $-0.10 · 2 analysts · -37% YoY
Next period, 2 analysts expect Silence Therapeutics PLC to earn $-0.17 a share (range $-0.24 – $-0.10), versus $-0.27 a year earlier. Full-year consensus is $-0.72, growing to $-0.77 the year after.
REVENUE · NEXT QUARTER
$4.5K
Range $0 – $27.0K · 2 analysts · -82% YoY
Revenue is expected to reach $4.5K (range $0 – $27.0K), -82.3% year-over-year. Full-year consensus is $324.7K, rising to $750.5K next year.
Top analysts covering Silence Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SLN.
#1
Keay Nakae
Chardan Capital · Rank #89
Buy
$27.00+97.2% to target
Overall win rate
43%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$75.00+447.8% to target
Overall win rate
36%
+ Follow
#3
MU
Michael Ulz
Morgan Stanley
Buy
$32.00+133.7% to target
Coverage
—
+ Follow
#4
RL
Richard Law CFA
Goldman Sachs
Sell
$4.00-70.8% to target
Coverage
—
+ Follow
#5
RL
Richard Law
Goldman Sachs
Sell
$3.00-78.1% to target
Coverage
—
+ Follow
SLN stock forecast FAQ
What is SLN's average 12-month price target?+
The 2 analysts with a live target average $53.50 for Silence Therapeutics PLC over the next 12 months, ranging from a $75.00 high to a $32.00 low.
Is SLN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SLN?+
The Street-high target is $75.00 (HC Wainwright & Co.), and the Street-low is $32.00 (Morgan Stanley). The average of all 2 active targets is $53.50.
How many Wall Street analysts cover SLN?+
3 analysts have an active rating on Silence Therapeutics PLC, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering SLN?+
Among analysts who currently cover SLN, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $27.00 target.
What is Silence Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.24 – $-0.10) across 2 analysts. Full-year EPS is projected at $-0.72, rising to $-0.77 the following year.
How much revenue is Silence Therapeutics PLC expected to report next quarter?+
Consensus revenue is $4.5K (range $0 – $27.0K). Full-year revenue is projected at $324.7K, growing to $750.5K next year.
Have analysts been upgrading or downgrading SLN lately?+
As of Sep, 3 of 3 firms rate SLN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SLN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
